and recommendation
Fibrocell Science, Inc. (FCSC)
Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.
FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.
- May 17, 2014 - 1:31pm | Earnings, Earnings Q1
- May 17, 2014 - 1:27pm | Earnings
- March 11, 2014 - 10:45pm | Earnings, Earnings Q4
- January 6, 2014 - 11:47am | BOD & C-Suite Updates
- November 16, 2013 - 6:54pm | Research Notes
- November 16, 2013 - 6:39pm | Research Notes
- October 2, 2013 - 11:49pm | Research Notes
- September 26, 2013 - 9:27am | Financings
- September 9, 2013 - 8:34am | Financings
- August 27, 2013 - 9:42am | BOD & C-Suite Updates
- August 19, 2013 - 12:09pm | Out and About
- July 2, 2013 - 9:55am | Research Notes, IP & Patents
- July 1, 2013 - 7:02pm | BOD & C-Suite Updates
- May 16, 2013 - 6:26pm | Out and About
- October 11, 2012 - 3:36pm | Financings
Pages
- « first
- ‹ previous
- 1
- 2
- 3